Clinical Trial

Finerenone Plus SGLT2 Inhibitors in Heart Failure

Study acronym: FIN-SGLT2-HF
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated January 20, 2026 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical study is to evaluate whether adding finerenone to standard treatment with a sodium-glucose cotransporter-2 (SGLT2) inhibitor provides additional benefits in patients with heart failure. The main question this study aims to answer is whether the combination of finerenone and an SGLT2 inhibitor improves clinical outcomes and is safe compared to treatment with an SGLT2 inhibitor alone. Participants will receive standard therapy with an SGLT2 inhibitor, with or without the addition of finerenone and will be followed to assess clinical outcomes and safety.
Trial Details
NCT Number NCT07351864
Lead Sponsor Mansoura University
Conditions Heart Failure
Enrollment 60 participants
Start Date 2026-01-18
Primary Completion 2026-04-30 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-20